The British Business Bank's 2026 equity tracker shows AI taking a record 44% of a UK smaller-business market that shrank to GBP12.3bn, with investment concentrating into fewer, larger deals. The same megadeals are redrawing regional shares and starving the spinout tier. CuspAI closed at $2.6bn with no UK backer as an EU fund circles, while Astral, Trimtech, StirlingX and Neuronostics show where capital still flows.
AI megadeals are draining Britain's seed and spinout tiers while growth-stage upside keeps landing with non-UK capital.
AI companies took a record 44% of UK smaller-business equity value in 2025, even as the total market shrank 4% to GBP12.3bn.
AI companies grabbed a record 44% of UK smaller-business equity funding in 2025. The British Business Bank reported it on 2 July, alongside a 4% drop in the total market to £12.3bn.
Seed deals fell 27% while the top 10 rounds alone took 23% of the cash. Money is concentrating in fewer, bigger AI bets, leaving first-time founders squeezed.
London's share of UK equity investment fell from 60% to 57% in 2025 as a handful of large AI and energy deals lifted the North West, Scotland and the South West.
London's share of UK equity investment fell from 60% to 57% in 2025, the British Business Bank found. The North West grew 82%, Scotland 74% and the South West 104%.
A handful of huge AI and energy deals drove the regional gains, not a broad shift. Next year's tracker will show whether regions keep gaining or London rebounds.
University spinout equity deals fell 33% by count and 51% by value in 2025, extending a pipeline already skewed to sub-GBP500,000 rounds.
University spinout equity deals fell 33% by number and 51% by value in 2025. Over a third of all spinout rounds closed below £500,000, the British Business Bank found.
A 7% fall in angel tax-relief investors was already under way before April's Venture Capital Trust cut hit. The smallest, riskiest spinout rounds have lost their main funding source.
CuspAI closed in late June at $2.6bn with Bezos Expeditions and Kleiner Perkins and no UK backer; now EQT and the EU's Scaleup Europe Fund want in.
CuspAI, the Cambridge AI materials company, closed its round at a $2.6bn valuation in late June with no UK investor at all. EQT (a European investment group) then entered talks for a further stake.
EQT manages the EU's €5bn Scaleup Europe Fund, aimed at keeping deep-tech winners anchored in Europe. Britain's biggest AI bets keep closing without a single domestic lead investor.
Astral Systems, a Bristol deep-tech firm, raised GBP23m to commercialise modular fusion reactors small enough to sell as products.
Astral Systems, a Bristol deep-tech firm, raised a £23m Series A to build modular fusion reactors that run several smaller reactions in parallel. Five funds backed the round, led by Mercia Ventures.
Fusion power could one day supply carbon-free electricity, but no design has reached commercial viability yet. Astral bets several smaller reactors cut the risk of one giant design failing.
Trimtech Therapeutics extended its seed round to GBP35.6m after Johnson & Johnson Innovation and BGF added $14m and took board seats.
Trimtech Therapeutics, a Cambridge biotech, extended its seed round to £35.6m after Johnson & Johnson's venture arm and BGF (a UK growth-capital investor) added $14m. Both took board seats.
A big drugmaker sitting on a seed-stage board often signals interest in the technology beyond just financial return. Trimtech's protein-degrader platform now has a major pharma partner watching closely.
StirlingX, founded in 2025, raised a GBP15m Series A for a sovereign defence-data platform, led by Ventura Capital with Rokos Capital Management.
StirlingX, a UK company founded in 2025, raised a £15m Series A to build a sovereign data and autonomy platform for defence and critical infrastructure. Ventura Capital led the round.
'Sovereign' means the data stays under UK control rather than on foreign-owned cloud servers. Rokos Capital Management co-invested alongside Ventura in the all-British round.
Neuronostics, an Exeter University spinout, raised GBP3m for BioEP, an EEG-based epilepsy biomarker, co-led by Empirical Ventures and The FSE Group with an Innovate UK grant.
Neuronostics, an Exeter University spinout, raised £3m in June for BioEP, its digital epilepsy biomarker. Empirical Ventures led the round, with a £400k Innovate UK grant on top.
BioEP reads routine electroencephalogram (EEG) recordings to help doctors diagnose epilepsy faster, without invasive tests. Blending a government grant with private investment is now common for early health-tech spinouts.
Sideways, pending two dated decision points. EQT's advanced talks for a further CuspAI stake are the immediate one: a signed term sheet would confirm the EU's Scaleup Europe Fund as the first sovereign vehicle to buy into a UK AI winner Britain's own funds passed over, a template EQT could then repeat on the next $1bn-plus round. The slower one is the 2026/27 British Business Bank tracker: whether the North West, Scotland and South West's 2025 gains, up 82%, 74% and 104% respectively, hold without a comparable AI or energy megadeal, or whether London's share reverts toward the 60% it held before 2025.
AI-assisted, human-edited under the editorial responsibility of Bannermedia Ltd. Reviewed by Ed Woodcock on 4 July 2026. Editorial standards.
